TL;DR
Get smart everyday buys delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Biden administration is exploring the legalization and research funding for ibogaine, a psychedelic with potential benefits for opioid addiction and PTSD. This marks a significant shift in drug policy, with bipartisan support emerging.
The Biden administration is considering measures to accelerate research and potential legalization of ibogaine, a psychedelic drug, to treat opioid addiction and PTSD, marking a notable shift in US drug policy.
Recent actions include the signing of an executive order by President Biden that supports fast-tracking FDA review processes for psychedelics, including ibogaine. The administration has allocated $50 million for research initiatives, focusing on state-led studies and human trials. While ibogaine remains classified as a Schedule I drug federally, these developments suggest a move toward broader acceptance and scientific evaluation.
Notably, figures such as Joe Rogan and some former military personnel have publicly advocated for the therapeutic potential of psychedelics, influencing political discourse. The executive order also extends the ‘Right to Try’ law to psychedelics, allowing terminal patients to access experimental treatments, which could include ibogaine.
Why It Matters
This shift indicates a potential end to longstanding bipartisan opposition to certain psychedelics, with implications for drug policy, mental health treatment, and veterans’ healthcare. If FDA approval is achieved, it could open the door for broader medical use of ibogaine and other psychedelics, transforming approaches to addiction and trauma recovery.
Ibogaine supplement for addiction recovery
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Traditionally, psychedelics have been associated with counterculture movements and faced strict federal regulation. However, recent years have seen increased scientific interest in their therapeutic benefits, especially for opioid addiction and PTSD. The Trump administration had already begun some steps toward easing restrictions, and now the Biden administration appears to be expanding on this momentum, with bipartisan support emerging among certain lawmakers and veteran groups. Learn more about the history of psychedelics and regulation.
“Psychedelics, once solely associated with counterculture, are now gaining mainstream political support, especially for their potential to treat PTSD and opioid addiction.”
— Mattha Busby, journalist
“The executive order aims to fast-track research and explore the therapeutic potential of psychedelics, including ibogaine, for medical use.”
— White House official (unnamed)
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It remains unclear whether the FDA will approve ibogaine for medical use within the current administration’s term, or how quickly regulatory hurdles will be overcome. The safety profile of ibogaine, especially when used improperly, continues to be a concern. Additionally, bipartisan political support is still emerging and may face opposition.
As an affiliate, we earn on qualifying purchases.
What’s Next
Next steps include the continuation of federally funded research, potential human trials, and ongoing discussions within the FDA regarding approval pathways. Monitoring legislative developments and public opinion will be crucial as these initiatives unfold. Stay updated on psychedelic research and policy changes.
PTSD and opioid addiction treatment products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is ibogaine and how does it work?
Ibogaine is a psychedelic compound derived from West African shrub bark, known for its potential to reduce opioid withdrawal symptoms and possibly treat PTSD by inducing recall of traumatic memories in a controlled setting. Read about the therapeutic potential of psychedelics like ibogaine.
Why is the Biden administration interested in ibogaine now?
The administration aims to explore new treatments for opioid addiction and PTSD, particularly for veterans, and to support scientific research into psychedelics’ therapeutic benefits.
Is ibogaine currently legal in the US?
No, ibogaine remains classified as a Schedule I drug federally, but recent executive actions are aimed at easing restrictions for research and potential medical use.
What are the risks associated with ibogaine?
Ibogaine can be dangerous if used improperly, with risks including cardiac issues and neurotoxicity. Proper medical supervision is essential for any therapeutic application.
Source: Vox
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
